PerkinElmer has entered into an agreement to acquire BioLegend, provider of life science antibodies and reagents, for approximately US$5.25 billion. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions. BioLegend provides academic and […]